Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$3.34 USD

3.34
521,514

+0.07 (2.14%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.34 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

by Zacks Equity Research

Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

    Zacks Equity Research

    Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%

    by Zacks Equity Research

    Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.

      Zacks Equity Research

      Alexion to Restructure Operations, to Lower Headcount by 20%

      by Zacks Equity Research

      Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.

        Zacks Equity Research

        Alexion (ALXN) Licenses Artubus Technology for Rare Diseases

        by Zacks Equity Research

        Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.

          Zacks Equity Research

          Celgene Issues Preliminary 2016 Results, Lifts 2017 View

          by Zacks Equity Research

          Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

            Zacks Equity Research

            Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

            by Zacks Equity Research

            Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.

              Zacks Equity Research

              Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

              by Zacks Equity Research

              Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                Zacks Equity Research

                The Medicines Co LDL-Lowering Drug Positive in Phase II

                by Zacks Equity Research

                The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.

                  Zacks Equity Research

                  Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

                  by Zacks Equity Research

                  Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

                    Zacks Equity Research

                    Bayer's sNDA for Stivarga Granted Priority Review in the U.S.

                    by Zacks Equity Research

                    Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.

                      Zacks Equity Research

                      Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

                      by Zacks Equity Research

                      Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

                        Zacks Equity Research

                        Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA

                        by Zacks Equity Research

                        Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.

                          Zacks Equity Research

                          Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher

                          by Zacks Equity Research

                          Fortress Biotech, Inc. (FBIO) moved big last session, as its shares jumped almost 21% on the day.

                            Zacks Equity Research

                            Galena Biopharma Reveals Regulatory Pathway for GALE-401

                            by Zacks Equity Research

                            Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.

                              Zacks Equity Research

                              Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

                              by Zacks Equity Research

                              Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.

                                Zacks Equity Research

                                Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

                                by Zacks Equity Research

                                Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

                                  Zacks Equity Research

                                  NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session

                                  by Zacks Equity Research

                                  NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.

                                    Zacks Equity Research

                                    Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

                                    by Zacks Equity Research

                                    Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

                                      Zacks Equity Research

                                      Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

                                      by Zacks Equity Research

                                      Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

                                        Zacks Equity Research

                                        Celgene (CELG) Otezla Approved in Japan for Two Indications

                                        by Zacks Equity Research

                                        Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

                                          Zacks Equity Research

                                          Roche Presents Positive Follicular Lymphoma Data on Gazvya

                                          by Zacks Equity Research

                                          Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                                            Zacks Equity Research

                                            Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                                            by Zacks Equity Research

                                            Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

                                              Indradip Ghosh headshot

                                              New Strong Buy Stocks for December 5th

                                              by Indradip Ghosh

                                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                                Zacks Equity Research

                                                Aimmune Closes Enrolment in Phase III Peanut Allergy Study

                                                by Zacks Equity Research

                                                Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101

                                                  Zacks Equity Research

                                                  Foamix Completes Enrolment in Phase III Acne Drug Studies

                                                  by Zacks Equity Research

                                                  Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies